Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 343,866 |
Reported balance
After 2026-10-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 45,838 · Balance 343,866 F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 384,058 |
Reported balance
After 2026-10-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-10-06 · Grant · Acquired 40,192 · Balance 384,058 F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 314,058 |
Reported balance
After 2026-10-06 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-10-06 · Tax withholding · Disposed 70,000 · Balance 314,058 F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-10-06 · Disposition to issuer · Disposed 404,608 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 14, 2021 Filed Oct 19, 2021 00:32 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,273 | $39.97 | $50,881.81 |
DisclosureSEC source: 0001437749-21-023859 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,198 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 28, 2021 Filed Oct 1, 2021 00:17 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 719 | $43.12 | $31,003.28 |
DisclosureSEC source: 0001437749-21-022970 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,471 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 22, 2021 Filed Sep 23, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-022535 · rdgdoc.xml · derivative · entry 6 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,853 Underlying: Common Stock · 10,000 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 197,707 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| September 22, 2021 Filed Sep 23, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $46.99 | $469,900.00 |
DisclosureSEC source: 0001437749-21-022535 · rdgdoc.xml · nonDerivative · entry 4 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,190 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.32 to $47.44, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 22, 2021 Filed Sep 23, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.64 | $16,400.00 |
DisclosureSEC source: 0001437749-21-022535 · rdgdoc.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2021 Filed Sep 23, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-022535 · rdgdoc.xml · derivative · entry 5 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,853 Underlying: Common Stock · 10,000 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 197,707 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| September 20, 2021 Filed Sep 23, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $46.89 | $468,900.00 |
DisclosureSEC source: 0001437749-21-022535 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,190 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.89 to $47.27, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 20, 2021 Filed Sep 23, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.64 | $16,400.00 |
DisclosureSEC source: 0001437749-21-022535 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 399 | $57.26 | $22,846.74 |
DisclosureSEC source: 0001437749-21-021221 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,190 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 00:05 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $53.12 | $531,200.00 |
DisclosureSEC source: 0001437749-21-021017 · rdgdoc.xml · nonDerivative · entry 4 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,589 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.19 to $54.83, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 00:05 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.64 | $16,400.00 |
DisclosureSEC source: 0001437749-21-021017 · rdgdoc.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 00:05 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-021017 · rdgdoc.xml · derivative · entry 6 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,853 Underlying: Common Stock · 10,000 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 197,707 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 00:05 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-021017 · rdgdoc.xml · derivative · entry 5 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,853 Underlying: Common Stock · 10,000 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 197,707 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 00:05 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $46.54 | $465,400.00 |
DisclosureSEC source: 0001437749-21-021017 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,589 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.4 to $47.02, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 00:05 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.64 | $16,400.00 |
DisclosureSEC source: 0001437749-21-021017 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2021 Filed Jul 22, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 8,854 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-017325 · rdgdoc.xml · derivative · entry 6 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,853 Underlying: Common Stock · 8,854 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 197,707 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| July 21, 2021 Filed Jul 22, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 8,854 | $45.61 | $403,830.94 |
DisclosureSEC source: 0001437749-21-017325 · rdgdoc.xml · nonDerivative · entry 4 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,589 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.14 to $46.03, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 21, 2021 Filed Jul 22, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 8,854 | $1.64 | $14,520.56 |
DisclosureSEC source: 0001437749-21-017325 · rdgdoc.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 19, 2021 Filed Jul 22, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-017325 · rdgdoc.xml · derivative · entry 5 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,707 Underlying: Common Stock · 10,000 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 197,707 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| July 19, 2021 Filed Jul 22, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $43.85 | $438,500.00 |
DisclosureSEC source: 0001437749-21-017325 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,589 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.43 to $44.52, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 19, 2021 Filed Jul 22, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.64 | $16,400.00 |
DisclosureSEC source: 0001437749-21-017325 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2021 Filed Jul 2, 2021 00:32 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 715 | $43.75 | $31,281.25 |
DisclosureSEC source: 0001437749-21-016269 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,589 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-014984 · rdgdoc.xml · derivative · entry 6 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,707 Underlying: Common Stock · 10,000 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 197,707 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $39.27 | $392,700.00 |
DisclosureSEC source: 0001437749-21-014984 · rdgdoc.xml · nonDerivative · entry 4 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,304 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.95 to $39.69, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.64 | $16,400.00 |
DisclosureSEC source: 0001437749-21-014984 · rdgdoc.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2021 Filed Jun 17, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-014984 · rdgdoc.xml · derivative · entry 5 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,707 Underlying: Common Stock · 10,000 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 197,707 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| June 14, 2021 Filed Jun 17, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $38.90 | $389,000.00 |
DisclosureSEC source: 0001437749-21-014984 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,304 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.40 to $39.37, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 14, 2021 Filed Jun 17, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.64 | $16,400.00 |
DisclosureSEC source: 0001437749-21-014984 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2021 Filed Jun 3, 2021 00:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 375 | $33.87 | $12,701.25 |
DisclosureSEC source: 0001437749-21-014005 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,304 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 19, 2021 Filed May 20, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-012837 · rdgdoc.xml · derivative · entry 6 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,707 Underlying: Common Stock · 10,000 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 197,707 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| May 19, 2021 Filed May 20, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $31.45 | $314,500.00 |
DisclosureSEC source: 0001437749-21-012837 · rdgdoc.xml · nonDerivative · entry 4 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,679 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.13 to $31.83, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 19, 2021 Filed May 20, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.64 | $16,400.00 |
DisclosureSEC source: 0001437749-21-012837 · rdgdoc.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2021 Filed May 20, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-012837 · rdgdoc.xml · derivative · entry 5 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,707 Underlying: Common Stock · 10,000 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 197,707 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| May 17, 2021 Filed May 20, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $30.12 | $301,200.00 |
DisclosureSEC source: 0001437749-21-012837 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,679 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.20 to $30.63, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 17, 2021 Filed May 20, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.64 | $16,400.00 |
DisclosureSEC source: 0001437749-21-012837 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2021 Filed Apr 22, 2021 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-009509 · rdgdoc.xml · derivative · entry 6 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,707 Underlying: Common Stock · 10,000 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 197,707 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| April 21, 2021 Filed Apr 22, 2021 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $32.26 | $322,600.00 |
DisclosureSEC source: 0001437749-21-009509 · rdgdoc.xml · nonDerivative · entry 4 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,679 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.44 to $32.87, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 21, 2021 Filed Apr 22, 2021 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.64 | $16,400.00 |
DisclosureSEC source: 0001437749-21-009509 · rdgdoc.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2021 Filed Apr 22, 2021 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-009509 · rdgdoc.xml · derivative · entry 5 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,707 Underlying: Common Stock · 10,000 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 197,707 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| April 19, 2021 Filed Apr 22, 2021 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $32.62 | $326,200.00 |
DisclosureSEC source: 0001437749-21-009509 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,679 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.45 to $33.02, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 19, 2021 Filed Apr 22, 2021 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.64 | $16,400.00 |
DisclosureSEC source: 0001437749-21-009509 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2021 Filed Apr 15, 2021 01:38 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 3,360 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-008953 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,679 F1 · price: The restricted stock award was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests in six (6) months. F2 · balance_after: The amount reported in Column 5 on Table I in the Form 4 filed by the reporting person on April 1, 2021 was incorrect by a deficit of 6,338 due to a typographical error. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 01:32 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 4,020 | $36.53 | $146,850.60 |
DisclosureSEC source: 0001437749-21-008331 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,981 F2 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 01:32 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,358 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-008331 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person was granted restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") on March 25, 2020. In accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. The grant was made in lieu of such reporting person receiving a 2020 cash performance bonus. F1 · price: The reporting person was granted restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") on March 25, 2020. In accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. The grant was made in lieu of such reporting person receiving a 2020 cash performance bonus. Read SEC document |
| March 26, 2021 Filed Mar 31, 2021 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,016 | $35.01 | $105,590.16 |
DisclosureSEC source: 0001437749-21-007721 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,981 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 24, 2021 Filed Mar 25, 2021 01:33 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-007081 · rdgdoc.xml · derivative · entry 6 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,707 Underlying: Common Stock · 10,000 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 197,707 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| March 24, 2021 Filed Mar 25, 2021 01:33 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $40.18 | $401,800.00 |
DisclosureSEC source: 0001437749-21-007081 · rdgdoc.xml · nonDerivative · entry 4 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,997 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $41.95, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 24, 2021 Filed Mar 25, 2021 01:33 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.64 | $16,400.00 |
DisclosureSEC source: 0001437749-21-007081 · rdgdoc.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2021 Filed Mar 25, 2021 01:33 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-007081 · rdgdoc.xml · derivative · entry 5 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,707 Underlying: Common Stock · 10,000 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 197,707 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| March 22, 2021 Filed Mar 25, 2021 01:33 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $37.80 | $378,000.00 |
DisclosureSEC source: 0001437749-21-007081 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,997 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.35 to $39.00, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.